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2013;310:609-16.MMENTARY‘‘Forgotten’’ valve or ‘‘enigmatic’’ valve? Further insights into the
tricuspid valve in patients undergoing mitral valve surgeryElizabeth H. Stephens, MD, PhD, and Michael A. Borger, MD, PhDCommonly referred to as the ‘‘forgotten valve,’’ the
tricuspid valve (TV) has received increasing attention in
recent years.1 Functional tricuspid regurgitation (fTR)
was often overlooked in the past, both because correction
of left-sided valvular pathology was thought to sufficiently
ameliorate fTR and because the optimal TV repair tech-
nique was unknown. We now know that fTR does not al-
ways improve after left-sided surgery and that residualtricuspid regurgitation (TR) imparts a poor long-term prog-
nosis. Residual TR is associated with a 2-fold risk of heart
failure1 and a 50% decrease in 5-year survival.2 Residual
TR is also progressive, with one-half of all patients having
progression by more than 2 grades 5 years after surgery.3 In
addition, isolated TV surgery for TR is associated with un-
acceptably high morbidity and mortality after mitral valve
(MV) surgery.4
In light of these findings, some investigators have argued
strongly for concomitant TV repair for patients with any
amount of fTR—or even for those with isolated tricuspid
annular dilation without fTR—when they undergo left-sided
valvular surgery.5 Several different tricuspid annuloplasty
rings have been designed for fTR, with none demonstrating
clear clinical superiority to date. Some evidence suggests,
however, that flexible rings may be associated with a lower
risk of dehiscence relative to rigid rings.6 Determining which
criteria should be applied to performing TV repair in patients
undergoing MV surgery remains a topic of debate.
Current guidelines recommend that severe TR should
be addressed at the time of MV surgery,7,8 because TVgery c November 2014
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Drepair does not add significantly to perioperative morbidity
or mortality and is associated with a minimal increase
in myocardial ischemic time.3,9 TV repair is also recom-
mended for patients undergoing MV surgery when they
have mild or moderate fTR and either TV annular dilation
or evidence of right heart failure, although this is a lower
class of recommendation.7,8 These recommendations are
based on studies that have shown that patients with
greater than 40 mm TV annular diameter on preoperative
echocardiography or greater than 70 mm anteroseptal to
anteroposterior commissural diameter measured during
direct intraoperative inspection are at risk for residual TR
and progression after MV surgery.3,10
Within this context, Rajbanshi and colleagues11 sought,
in the study published in this issue of the Journal, to further
investigate late fTR after MV surgery for degenerative
mitral regurgitation. Their cohort consisted of 683 patients
who underwent isolated MV repair and 64 who underwent
MV replacement between 1995 and 2006. Patients undergo-
ing MV surgery who had severe TR or moderate TR with
right heart failure symptoms, structural abnormalities of
the TV, dilated right atrium and ventricle, severe pulmonary
hypertension, or atrial fibrillation underwent concomitant
TV repair and were therefore excluded. Furthermore, pa-
tients who had pacemaker or defibrillator leads placed
before or after surgery were excluded. Within this study
cohort, 5% of patients had no preoperative fTR, 80% had
trace or mild fTR, and 15% had moderate fTR. Mean
follow-up was 7 years, and patients were divided into 3
groups according to the length of echocardiographic
follow-up: less than 1 year, 1 to 5 years, and longer than 5
years.
Although this study addresses an important clinical
dilemma, namely optimal management of fTR in patients
undergoingMV surgery, it does have several key limitations.
The division of patient follow-up into 3 time periods sub-
stantially decreases its power and thereby increases the
risk of a type II statistical error. For longitudinal studies,
Kaplan-Meier curves and adjustment for competing risks
(such as death and TV repair) would be more appropriate.
Additionally, excluding patients who received pacemakers
after surgery (the number of patients excluded for this
reason is unknown) seems inappropriate given that the deci-
sion to repair the TV must be made before surgery. Further-
more, the incomplete follow-up in the less than 1 year and 1
to 5 years follow-up groups (both<50%) could introduce
selection bias, making interpretation of these results
difficult.
The most important insights that can be ascertained
from this study come from those patients who underwent
echocardiographic follow-up more than 5 years after MV
surgery. Within this subgroup, only 12 patients (6%)
developed severe TR, and a further 4 patients required
TV surgery at some time during the follow-up period.The Journal of Thoracic and CarUnfortunately, preoperative TV annular dimensions and
extent of tricuspid leaflet tethering were not reported.
Not surprisingly, Rajbanshi and colleagues11 were unable
to demonstrate a significant effect of MV repair versus
replacement on the development of subsequent TR. With
these limitations in mind, it appears that patients with
degenerative MV disease and moderate or less TR without
the previously mentioned indications for TV repair have a
low incidence of severe TR 5 years after MV surgery. Raj-
banshi and colleagues11 were unable to identify any vari-
ables associated with development of late TR on
multivariate analysis. Although they concluded that timing
of MV repair in degenerative MV disease may influence
progression of fTR, this conclusion was based on univari-
ate analysis showing higher pulmonary arterial pressures
and larger left atrial size in patients with TR progression,
variables that were not significant on multivariate analysis.
Further data are required in order to support such a
hypothesis.
In conclusion, the risk of development of significant TR
appears to be low in highly selected patients undergoing
mitral procedures for degenerative disease, and this risk is
not affected by the choice to perform MV repair versus
replacement. The critical question of when to perform TV
repair in patients with moderate or less fTR remains contro-
versial and requires further study. Perhaps it is time to start
addressing the TV as the ‘‘enigmatic valve,’’ rather than as
the ‘‘forgotten valve.’’
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